Ascenta

May 19, 2017

502 Views



 

2016

 

Methods and reagents for detecting bioactive lipids

RA Sabbadini, WA Garland, G Hansen - US Patent 9,274,129, 2016 - Google Patents

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon 

 

2015

 

Immune-derived moieties reactive against lysophosphatidic acid

RA Sabbadini, WA Garland, G Hansen - US Patent 9,217,749, 2015 - Google Patents

US9217749B2 - Immune-derived moieties reactive against lysophosphatidic acid - Google Patents. Immune-derived moieties reactive against lysophosphatidic acid. Download PDF Info. Publication number US9217749B2. US9217749B2 …  Cited by 6 Related articles All 4 versions 

 

Novel bioactive lipid derivatives, and methods of making and using the same

RA Sabbadini, WA Garland - US Patent App. 14/451,394, 2015 - Google Patents

US20150031055A1 - Novel bioactive lipid derivatives, and methods of making and using the same - Google Patents. Novel bioactive lipid derivatives, and methods of making and using the same. Download PDF Info. Publication …

 

2013

 

 

Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease

J FioritoF Saeed, H Zhang, A Staniszewski… - European journal of …, 2013 - Elsevier

… cGMP while the remaining PDEs have mixed specificity (PDE1, PDE2, PDE3, PDE10, and PDE11) [2], [3]. Among all PDEs, PDE5 is widely expressed in a variety of tissues, such as brain, smooth muscle, lung, platelets and kidney (see Gene Logic's ASCENTA System and [4], [5 …Cited by 64 Related articles All 6 versions

 

Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines

SJ Demarest, J Gardner, MC Vendel, E Ailor… - Biochemistry, 2013 - ACS Publications

 

 

2012

 

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study

C Aghajanian, MW Sill, AA Secord, MA Powell… - Gynecologic …, 2012 - Elsevier

… Gene expression analysis to characterize the expression level of PARP1 and PARP1 related genes using a microarray expression generated from well annotated diseased and normal tissue samples has been performed (ASCENTA database; Gene Logic, Gaithersburg) …Cited by 27 Related articles All 5 versions

 

Method for treatment of pancreatitis

LA TartagliaTM Barnes, RM Coopersmith… - US Patent App. 13 …, 2012 - Google Patents

US20120009183A1 - Method for treatment of pancreatitis - Google Patents. Method for treatment of pancreatitis. Download PDF Info. Publication number US20120009183A1. US20120009183A1 US13/171,058 US201113171058A …All 2 versions 

 

Treatment of breast cancer with iodonitrobenzamides in combination with anti-tumor agents

BM Sherman, C Bradley… - US Patent App. 13/430,475, 2012 - Google Patents

US20120269861A1 - Treatment of breast cancer with iodonitrobenzamides in combination with anti-tumor agents - Google Patents. Treatment of breast cancer with iodonitrobenzamides in combination with anti-tumor agents. 

 

2011

 

A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma

RA Lacour, E Euscher, EN Atkinson, CC Sun… - International Journal of …, 2011 - ijgc.bmj.com

… Likewise, defects in DNA mismatch repair and TP53 have been recognized as factors in uterine CS tu- morigenesis.23 This, along with the suggestion of PARP over- expression in uterine CS (ASCENTA database; Gene Logic, Gaithersburg, Md), brings the exploration of novel …  Cited by 44 Related articles All 6 versions

 

Novel estrogen-related genes and potential biomarkers of ovarian endometriosis identified by ifferential expression analysis

K Vouk, T Šmuc, C Guggenberger… - The Journal of steroid …, 2011 - Elsevier

… These were obtained from the Genelogic ASCENTA ® System (http://www.genelogic. com), a commercial database that provides microarray gene-expression profiles from clinically relevant normal and diseased human tissue sample sets …Cited by 30 Related articles All 7 versions

 

Biomarker for microdomain disease

K Higashi, T Mikami - US Patent App. 13/120,843, 2011 - Google Patents

… Analysis of GM2A Gene in Obese Patient; Distribution of expression of GM2A gene in a human normal tissue was examined using Ascenta of Gene Logic Inc., which is a commercially available database listing gene expression data by the tissue and the disease of a human …

 

 

2010

 

Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy

H Hackl, G Stocker, P Charoentong, B Mlecnik… - Pharmacology & …, 2010 - Elsevier

Skip to main content Skip to article … Cited by 10 Related articles All 6 versions

 

A novel adipokine GM2AP impairs insulin signaling

K Higashi, T Mikami, T Yamada, H Kawashima… - Biochemical and …, 2010 - Elsevier

 2.8. Gene logic ASCENTA database … With the Gene Logic ASCENTA database, p-values were calculated using the Welch's t-test (for unequal variance) with the two sample set means for the selected gene fragment. 3. Results. 3.1 

Cited by 5 Related articles All 7 versions

 

Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types

V Ossovskaya, IC Koo, EP Kaldjian… - Genes & …, 2010 - journals.sagepub.com

Poly (ADP-ribose) polymerase-1 (PARP1) is a key facilitator of DNA repair and is implicated in pathways of tumorigenesis. PARP inhibitors have gained recent att...  Cited by 160 Related articles All 5 versions

 

Selection of relevant species

M Subramanyam, N Rinaldi… - Pharmaceutical …, 2010 - Wiley Online Library

Page 1. 1 Selection of Relevant Species MEENA SUBRAMANYAM , PhD , NICOLA RINALDI , PhD , ELISABETH MERTSCHING , PhD , and DAVID HUTTO , PhD, DVM Contents 1 Introduction 1.1 Species Selection: Biologics …

 Cited by 14 Related articles All 2 versions

 

 

 

Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents

BM Sherman, C Bradley - US Patent 7,732,491, 2010 - Google Patents

In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer …  Cited by 36 Related articles All 4 versions 

 

Method for treating inflammatory diseases of the digestive tract

LA TartagliaTM Barnes, RM Coopersmith… - US Patent …, 2010 - Google Patents

US7842709B2 - Method for treating inflammatory diseases of the digestive tract - Google Patents. Method for treating inflammatory diseases of the digestive tract. Download PDF Info. Publication number US7842709B2. US7842709B2 …Cited by 

 

Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents

BM Sherman, C Bradley - US Patent App. 12/496,593, 2010 - Google Patents

US20100003192A1 - Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents - Google Patents. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents. Cited by 6 Related articles All 2 versions 

 

Methods for breast cancer screening and treatment

D White, S Jin, RM Coopersmith… - US Patent App. 12 …, 2010 - Google Patents

US20100029734A1 - Methods for breast cancer screening and treatment - Google Patents. Methods for breast cancer screening and treatment. Download PDF Info. Publication number US20100029734A1. US20100029734A1 …

Cited by 6 Related articles All 2 versions 

[PDF] googleapis.com

Method for reducing gastrointestinal adverse effects of cytotoxic agents

SR Donahue, JJ Byrnes - US Patent App. 12/704,286, 2010 - Google Patents

A method for moderating a gastrointestinal adverse effect induced by at least one cytotoxic agent, for example ionizing radiation and/or at least one chemotherapeutic agent, in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor …

 

Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents

BM Sherman, C Bradley - US Patent App. 12/502,943, 2010 - Google Patents

US20100009930A1 - Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents - Google Patents. Treatment of uterine cancer and ovarian cancer with a parp inhibitor …  Cited by 6 Related articles All 2 versions 

 

Methods and compositions for treating skin conditions

K Pojasek, D Steinberg, D Zohar - US Patent App. 12/599,911, 2010 - Google Patents

US20100278784A1 - Methods and compositions for treating skin conditions - Google Patents. Methods and compositions for treating skin conditions. Download PDF Info. Publication number US20100278784A1. US20100278784A1 …

Cited by 94 Related articles All 2 versions 

 

2009

Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer's disease mouse model

D Puzzo, A Staniszewski, SX Deng… - Journal of …, 2009 - Soc Neuroscience Cited by 242 Related articles

 

[PDF] Novel PDE5 Inhibitors as a Therapeutic Tool Against Alzheimer's Disease O Arancio - alz.washington.edu

… from APP/PS1 mice Page 13. Sildenafil decreases Aβ levels in APP/PS1 mice Page 14. Is there any PDE5 in human hippocampus? Page 15. Database of human brain Gene Logic's ASCENTA System 0/24 20/24 3/24 0/28 23/28 3/ 28 Page 16. Relative expression (× 10 -6 ) 0 40 … All 2 versions 

 

Methods of treating and preventing acute myocardial infarction

WR Baumbach, H Shankar… - US Patent App. 12 …, 2009 - Google Patents

… Alternatively, commercial products such as the ASCENTA® system (GeneLogic, Gaithersburg, Md.) provide expression data from healthy and diseased tissues that have been pre-screened and analyzed. Thus, the search for

Cited by 2 Related articles All 2 versions 

 

Method for treating er+ breast cancer

RM Coopersmith, DW White, S Jin… - US Patent App. 12 …, 2009 - Google Patents

US20090012052A1 - Method for treating er+ breast cancer - Google Patents. Method for treating er+ breast cancer. Download PDF Info. Publication number US20090012052A1. US20090012052A1 US12/100,053 US10005308A …

Cited by 7 Related articles All 2 versions 

 

Method for treatment of pancreatitis

LA TartagliaTM Barnes, RM Coopersmith… - US Patent App. 12 …, 2009 - Google Patents

A method for treating acute or chronic pancreatitis in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor.  Related articles All 2 versions

 

Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents

BM Sherman, C Bradley… - US Patent App. 12/269,833, 2009 - Google Patents

US20090123419A1 - Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents - Google Patents. Treatment of uterine cancer and ovarian cancer with a parp inhibitor …

 

 

2008

Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth

Z Yan, H Zou, F Tian, JR Grandis, AJ Mixson… - Molecular cancer …, 2008 - AACR

Skip to main content. AACR Journals: Cancer Discovery; Cancer Epidemiology, Biomarkers & Prevention; Cancer Immunology Research; Cancer Prevention Research; Cancer Research; Clinical Cancer Research; Molecular Cancer Research; Molecular Cancer Therapeutics …Cited by 75 Related articles All 9 versions

 

Breast cancer screening and treatment methods

RM Coopersmith, DW White, S Jin… - US Patent App. 11 …, 2008 - Google Patents

US20080132474A1 - Breast cancer screening and treatment methods - Google Patents. Breast cancer screening and treatment methods. Download PDF Info. Publication number US20080132474A1. US20080132474A1 US11 …Cited by 2 Related articles All 2 versions 

 

Method for reducing or alleviating inflammation in the digestive tract

LA TartagliaTM Barnes, RM Coopersmith… - US Patent App. 11 …, 2008 - Google Patents

US20080234345A1 - Method for reducing or alleviating inflammation in the digestive tract - Google Patents. Method for reducing or alleviating inflammation in the digestive tract. Download PDF Info. Publication number US20080234345A1 …Cited by 1 Related articles All 2 versions 

 

Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same

RA Sabbadini, WA Garland, G Hansen - US Patent App. 11/755,485, 2008 - Google Patents

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon …Cited by 4 Related articles All 2 versions 

 

Protein kinase inhibitors

DJ Bearss, CL Grand, XH Liu… - US Patent App. 11 …, 2008 - Google Patents

US20080207632A1 - Protein kinase inhibitors - Google Patents. Protein kinase inhibitors. Download PDF Info. Publication number US20080207632A1. US20080207632A1 US11/932,617 US93261707A US2008207632A1 US …Related articles All 2 versions 

 

 

2007

 

BREAST CANCER SCREENING AND TREATMENT METHODS

RM Coopersmith, DW White, S Jin… - US Patent App. 11/ …, 2007 - Google Patents ... LOUIS, MO 63105 (73) Assignee: Gene Logic Inc., Gaithersburg, MD (US) (21) Appl.No.: 11/935,870 (22) Filed: Nov. 6, 2007 Related US Application Data (60) Provisional application No. 60/865,094, filed on Nov. 9, 2006. (51) Int. CI. ...

 

Bioinformatics approaches in the study of cancer

DA Hanauer, DR Rhodes… - Current molecular …, 2007 - ingentaconnect.com

... Gene Logic also offers their ASCENTA® System [20] which contains about 8,700 Affymetrix GeneChip® mouse, human, and rat arrays. ... projects ranging from management of clinical trials to tools for analysis of gene expression data. ... [19] http://www.genelogic.com/docs/pdfs ...Cited by 24 - Related articles - BL Direct - 

2006

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member

JM O'toole, KE Rabenau, K Burns, D Lu… - Cancer research, 2006 - AACR

Skip to main content …Cited by 135 Related articles

Ron in Breast Development and Cancer 

SE Waltz - 2006 - apps.dtic.mil

… Western blot analyses. In addition, through access to the Gene Logic Ascenta database, we were able to assess RON expression profile in a variety of cancer tissues as well as in the NCI-60 cancer cell line panel. Table 1 is …Related articles 

 

[PDF] Identifizierung und funktionelle Charakterisierung neuer Interaktionspartner des renalen ROMK-Kaliumkanals

F Bundis - 2006 - core.ac.uk

Page 1. Identifizierung und funktionelle Charakterisierung neuer Interaktionspartner des renalen ROMK-Kaliumkanals Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften vorgelegt beim Fachbereich für Biochemie, Chemie und Pharmazie …Related articles 

 

The role of bioinformatics in genomic medicine

AHC van KampenAJG Horrevoets - Cardiovascular Research, 2006 - Springer

Ascenta Gene expression database www.genelogic.com Bodymap Data bank of expression bodymap.ims.u-tokyo.ac.jp information CaGE Cardiac Gene Expression www.cage.wbmei.jhu. edu knowledge base EBI European Bioinformatics www.ebi.ac.uk (SRS, MIAME, Institute …Cited by 4 Related articles All 7 versions

 

Targeting the lymphotoxin-β receptor with agonist antibodies as a potential cancer therapy

M Lukashev, D LePage, C Wilson, V Bailly, E Garber… - Cancer research, 2006 - AACR

Skip to main content. AACR Publications: Cancer Discovery; Cancer Epidemiology, Biomarkers & Prevention; Cancer Immunology Research; Cancer Prevention Research; Cancer Research; Clinical Cancer Research; Molecular Cancer Research; Molecular Cancer Therapeutics

 

 

2005

 

 Methods for enhancing gene expression analysis

U Scherf, G Hoke, D Wilson, D Barnes - US Patent App. 10/504,072, 2005 - Google Patents

… filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc 2004-06-04 Priority to US10/504,072 priority patent/US20050221310A1/en 2004-06-04 Priority to PCT/US2004/017621 priority patent/WO2005003370A2/en 2005-04-11 Assigned to GENE LOGIC, INC … Cited by 1 Related articles All 2 versions 

 

Methods for enhancing gene expression analysis

U Scherf, G Hoke, D Wilson, D Barnes - US Patent App. 10/948,635, 2005 - Google Patents

…to PCT/US2004/017621 priority patent/WO2005003370A2/en 2004-09-24 Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc 2004-09-24 Priority to US10/948,635 priority patent/US20050170375A1/en 2005-04-18 Assigned to GENE LOGIC …

 

2004

The ASCENTA system reveals candidate cancer treatment targets by their co-regulation across the human body: Using a known target, CDC2, to seed discovery

R Nadimpalli, C Coberley, D Schwartz, G Shen, L Mertz… - 2004 - AACR

Skip to main content. AACR Publications: Cancer Discovery; Cancer Epidemiology, Biomarkers & Prevention; Cancer Immunology Research; Cancer Prevention Research; Cancer Research; Clinical Cancer Research; Molecular Cancer Research; Molecular Cancer Therapeutics …

 

Match/X, a gene expression pattern recognition algorithm used to identify genes which may be related to CDC2 function and cell cycle regulation

C Coberley, M Elashoff, L Mertz - Cell Cycle, 2004 - Taylor & Francis

… authors contributed equally to this work *Correspondence to: Lawence Mertz; Gene Logic Inc.; 610 … 20879 USA; Tel.: 240.364.6227; Fax: 240.364.6262; Email: lmertz@genelogic.com Received 03 … sets used for Match/X™ validation were derived from the ASCENTA™ System, an …

Cited by 3 Related articles All 3 versions

 

[PDF] MICROARRAYS IN MEDICAL RESEARCH

M Kamarinos, M Waltham - asbmb.org.au

… Microarray/main.html). GeneLogic's Affymetrix subscription database (ASCENTA system; www.genelogic.com) is particularly powerful boasting expression profiles from approximately 9,000 human, mouse and rat samples. In order to …

 

Disclaimer: The information provided here is not exhaustive by any means. Always consult your doctor or other qualified healthcare provider with any questions you may have regarding a medical condition, procedure, or treatment, whether it is a prescription medication, over-the-counter drug, vitamin, supplement, or herbal alternative.